Abstract: Disclosed is technology to solve the problem in a world that is inundated with microbes of keeping food fresher for longer and shelf-life extension to enhance food security and safety without refrigeration/freezing, chemical preservatives integrated into the food product and/or physically/chemically altering the food product. Aspects of the technology are directed at the three levels of the food delivery system; namely, supermarket style display ware, bulk packaging and overseas container. This technological problem is solved by situating on food contacting/abutting surfaces of display ware, bulk packaging and oversees containers an antimicrobe agent formulated as a composition comprised of (i) between about 0.25% (w/w) to about 0.75% (w/w) benzalkonium chloride; (ii) between about 0.02% (w/w) to about 1.00% (w/w) of a kill agent selected from the group consisting of hydrogen peroxide and phenoxyethanol; (iii) between about 0.25% (w/w) to about 0.

Abstract: The patent disclosure covers antibiofilm compositions, wound dressings, cleaning methods and treatment methods. The antibiofilm composition is comprised of between about 0.05% (w/w) to about 0.20% (w/w) benzalkonium chloride; between about 0.20% (w/w) to about 0.50% (w/w) 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride; between about 0.25% (w/w) to about 0.75% (w/w) phenoxyethanol and between about 98.55% (w/w) to about 99.5% (w/w) deionized water. Disclosed are wound dressings having a reservoir of the antibiofilm composition. In the field of inanimate surfaces, disclosed are methods to clean and clean and protect inanimate surfaces. In the field of animate surfaces, disclosed are methods for the treatment of nose, ear and skin/facial disorders associated with biofilms.

Abstract: This patent is for a kill and protect surface disinfectant and a hand sanitizer for combatting contact infection spread. The kill and protect surface disinfectant composition is comprised of between about 0.20% (w/w) to about 1.00% (w/w) benzalkonium chloride; between about 0.25% (w/w) to about 3.00% (w/w) hydrogen peroxide; between about 0.25% (w/w) to about 0.75% (w/w) 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride and between about 95.25% (w/w) to about 99.30% deionized water. The hand sanitizer is comprised of between about 0.05% (w/w) to about 0.20% (w/w) benzalkonium chloride; between about 0.20% (w/w) to about 0.50% (w/w) 3-(tri-methoxysilyl)propyldimethyl octadecyl ammonium chloride; between about 0.25% (w/w) to about 0.75% (w/w) phenoxyethanol and between about 98.55% (w/w) to about 99.5% (w/w) deionized water. The two work together to safeguard a community from contact infection spread.

Abstract: The invention relates to improved products, processes, and therapeutic methods relating to hematopoietic stem cells and hematopoietic stem cell transplantation. Included are methods for improving transplant efficiency of cord blood units comprising use of mixtures of expanded CD34+/CD 133? HSCs and unexpanded CD133+ HSCs for IBM administration.

Abstract: The invention relates to products, processes, and therapeutic methods for restoring blood flow to tissues at risk of becoming or being ischemic by inducing angiogenesis and/or vasculogenesis in tissues in need thereof by administering endothelial colony forming cells alone or in combination with other cell types and/or agents. In one aspect, the invention is useful for inducing angiogenesis and/or vasculogenesis in patients with ischemic disease including ischemic heart disease, and other ischemic vascular disorders.

Abstract: The present invention provides assays to identify compounds that affect microglial cell activation, and specifically assays to identify compounds that affect secretion of cytokines from these microglial cells by modulating PGE2-mediated activity. The assays of the invention include assays for testing microglial cell activation by contacting microglia with compounds that modulate ?-amyloid PGE2-mediated activation, which can be identified by cellular activity such as secretion of cytokines, e.g., TNF-? and IL-1?,. The effect of the candidate compound can be determined by comparing the effect with a control culture which is not contacted with the compound, or by comparing the effect with a standardized profile.

Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5-7.0.

Abstract: Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.

Abstract: Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.